United Health Products partners with NAMSA to sponsor clinical study of CelluSTAT for FDA PMA

United Health Products, Inc.

NAMSA will serve as regulatory sponsor, seeking an IDE to conduct a clinical study of CelluSTAT Hemostatic Gauze.
UHP will hold exclusive right of reference to all study data for use in a revised PMA application.
The study is part of efforts to resolve the outstanding FDA Warning Letter.
NAMSA has decades of experience in clinical trial management for Class III hemostatic agents and FDA CDRH.
CEO Brian Thom expressed confidence in NAMSA's ability to gain IDE approval and efficiently sponsor the study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.